{"entity":{"id":"nct06202313","kind":"trial","name":"Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer","aka":[],"tldr":"A phase 2 trial of cadonilimab and eribulin in triple-negative breast cancer, run by Shengjing Hospital, not yet recruiting.","summary":"Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer is a phase 2, randomised interventional study registered as NCT06202313 by Shengjing Hospital, with a registry enrolment figure of 128 participants, started 2024-02-10 and due to reach its primary completion in 2025-12-30. Interventions recorded: Cadonilimab; Eribulin. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"Recurrent or metastatic incurable triple negative breast cancer confirmed by histology and/or cytology\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06202313","url":"https://clinicaltrials.gov/study/NCT06202313"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy"],"targets":[],"drugs":["cadonilimab","eribulin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06202313","phase":"2","setting":"A Multicenter, Randomized, Controlled, Open Label Clinical Study on the Treatment of Recurrent or Metastatic Triple Negative Breast Cancer With Cadonilimab Combined With Eribulin Versus Eribulin Alone","sponsor":"Shengjing Hospital","participation":[{"nct":"NCT06202313","source":"https://clinicaltrials.gov/study/NCT06202313","fetchedAt":"2026-10-07T16:54:18.114Z","studySha256":"0256afe2ba785fe8047a121606ba852c27d3cc009d57e9f20cc243a42a683ef9","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2024-01-11","leadSponsor":"Shengjing Hospital","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":128,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2024-02-10","startedType":"estimated","enrolled":128,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06202313/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"cadonilimab","kind":"drug","name":"Cadonilimab","route":"/drugs/cadonilimab/"},{"id":"eribulin","kind":"drug","name":"Eribulin","route":"/drugs/eribulin/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}